首页> 外文期刊>海南医科大学学报(英文版) >Clinical significance of serum tumor markers CA153, CA125, CA72-4 and FIB, IL-6 levels detection in ovarian cancer
【24h】

Clinical significance of serum tumor markers CA153, CA125, CA72-4 and FIB, IL-6 levels detection in ovarian cancer

机译:血清肿瘤标志物CA153,CA125,CA72-4和FIB,IL-6水平检测在卵巢癌中的临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate the clinical significance of serum tumor markers CA153, CA125, CA72-4 and FIB, IL-6 levels in the detection of ovarian cancer. Methods: A total of 40 patients with ovarian carcinoma treated in our hospital from September 2015 to June 2017 were selected as the ovarian cancer group; 40 patients with benign ovarian tumors in the same period were selected as the benign ovarian tumor group; 40 healthy subjects were selected as the control group. The levels of tumor markers CA153, CA125, CA72-4 and FIB, IL-6 were compared between the three groups. Results: The CA153, CA125, CA72-4 and FIB, IL-6 levels of the ovarian cancer group were significantly higher than those in benign ovarian tumor group and the control group; these levels in the benign ovarian tumor group was not significantly different from those in the control group. With the increase of clinical phase, the levels of CA153, CA125 and CA72-4 in patients with ovarian cancer were gradually increased, and the levels in phase Ⅲ and Ⅳ were significantly higher than those in phase Ⅱ and in phase I;and the CA125 in phase Ⅱ was significantly higher than that in phase Ⅰ. The levels of FIB and IL-6 in phase Ⅱ and in phase Ⅲ, Ⅳ were significantly higher than those in phase I; the IL-6 level in phase Ⅲ, Ⅳ was significantly higher than that in phase Ⅱ. Conclusion: Serum tumor markers CA153, CA125, CA72-4 and FIB, IL-6 levels for ovarian cancer detection can be helpful for clinical diagnosis and worthy of promotion.
机译:目的:探讨血清肿瘤标志物CA153,CA125,CA72-4和FIB,IL-6水平检测卵巢癌的临床意义。方法:从2015年9月到2017年6月,我们院长40例卵巢癌患者被选为卵巢癌组; 40例良性卵巢肿瘤在同一时期的患者被选为良性卵巢肿瘤组;选择40个健康受试者作为对照组。在三组之间比较了肿瘤标志物Ca153,Ca125,Ca72-4和Fib,IL-6的水平。结果:Ca153,Ca125,Ca72-4和Fib,IL-6水平卵巢癌组显着高于良性卵巢肿瘤组和对照组;良性卵巢肿瘤组中的这些水平与对照组中没有显着差异。随着临床阶段的增加,卵巢癌患者Ca153,Ca125和Ca72-4的水平逐渐增加,Ⅲ期和Ⅳ期的水平明显高于Ⅱ期和I阶段;和CA125 Ⅱ期明显高于Ⅰ期。 Ⅱ阶段和Ⅲ期,Ⅳ期的FIB和IL-6水平明显高于I阶段; Ⅲ期IL-6水平显着高于Ⅱ期Ⅱ期。结论:血清肿瘤标志物Ca153,Ca125,Ca72-4和Fib,IL-6卵巢癌检测水平可能有助于临床诊断和值得推广。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2018年第1期|101-104|共4页
  • 作者单位

    Department of Gynecology,Hengshui People's Hospital,Hengshui,Hebei Province,053000,China;

    Department of Gynecology,Hengshui People's Hospital,Hengshui,Hebei Province,053000,China;

    Department of Gynecology,Hengshui People's Hospital,Hengshui,Hebei Province,053000,China;

    Department of Gynecology,Hengshui People's Hospital,Hengshui,Hebei Province,053000,China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号